Eagle Pharmaceuticals
Presença
Eagle Pharmaceuticals é uma das ...
Eagle Pharmaceuticals é uma empresa listada sob o símbolo EGRX (US).
Fusão, aquisição e financiamento envolvendo Eagle Pharmaceuticals.
- Revelation Pharma has announced the acquisition of Eagle Pharmaceuticals (publicado em 24 de julho de 2023).
Executivos
Veja o organograma con seus 8 executivos principais
Biografias mais buscadas da Eagle Pharmaceuticals
- Michael Graves, Interim Executive Chairman of the Board
- Robert Glenning, Director
- Richard Edlin, Director
Recentes movimentos de executivos em Eagle Pharmaceuticals
- Steven Ratoff antes Non-Executive Director, foi promovido a Non-Executive Director and Interim Chief Financial Officer (Notícia publicada em 11 de março de 2024).
- Brian Cahill, Chief Financial Officer, deixou a Companhia (Notícia publicada em 11 de março de 2024).
- Scott Tarriff, President, Chief Executive Officer and Director, deixou a Companhia (Notícia publicada em 29 de novembro de 2023).
Criar um alerta
para seguir os movimentos de executivos da Eagle Pharmaceuticals.
Farmacêutica
Eagle Pharmaceuticals possui 1.869 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Johnson & Johnson (Estados Unidos).
Popular M&A news in Farmacêutica
- AstraZeneca has announced the acquisition of Fusion Pharma (publicado em 23 de março de 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publicado em 19 de março de 2024).
- Frontier Medicines acaba de anunciar uma arrecadação de fundos de 80 milhões de dólares. (publicado em 27 de fevereiro de 2024).
Outros contatos sugeridos na indústria do Farmacêutica
Notícias
Últimos comunicados de imprensa de Eagle Pharmaceuticals
- Eagle Pharmaceuticals’ Japanese Licensing Partner SymBio Announces Completion of Clinical Trial Enrollment for TREAKISYM® Rapid Infusion Liquid Bendamustine Formulation | Eagle Pharmaceuticals Investor Center
- Press Releases | Eagle Pharmaceuticals Investor Center
- Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Results | Eagle Pharmaceuticals Investor Center
- Eagle Pharmaceuticals to Discuss Fourth Quarter and Full Year 2019 Financial Results on March 2, 2020 | Eagle Pharmaceuticals Investor Center
- Eagle Pharmaceuticals Receives Final FDA Approval for PEMFEXY™ (Pemetrexed for Injection) | Eagle Pharmaceuticals Investor Center
- Eagle Pharmaceuticals to Develop Dantrolene Sodium for Potential Treatment of Alzheimer’s Disease in Collaboration With University of Pennsylvania | Eagle Pharmaceuticals Investor Center
- Eagle Pharmaceuticals Resubmits NDA for RYANODEX for Exertional Heat Stroke | Eagle Pharmaceuticals Investor Center
- Tyme Technologies and Eagle Pharmaceuticals Announce Strategic Collaboration to Advance Innovative Oral SM-88 for the Treatment of Patients with Cancer | Eagle Pharmaceuticals Investor Center
- Eagle Pharmaceuticals and NorthShore University HealthSystem to Study Dantrolene Sodium for the Treatment of Concussion and Other Forms of Traumatic Brain Injury | Eagle Pharmaceuticals Investor Center
- Press Releases | Eagle Pharmaceuticals Investor Center
- View more press releases Close
Redes sociais sobre Eagle Pharmaceuticals
- Eagle Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
- Eagle Pharmaceuticals na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Daniel O'Connor 
Ligue para a Eagle Pharmaceuticals em +1 201...
